Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. | 2001 Apr |
|
| [Leu-enkephalin homogeneously labeled with tritium in studying the Selank inhibiting effect on the enkephalin-degrading enzymes of human plasma]. | 2004 May-Jun |
|
| [Effects of the new peptide anxiolytic drug selank on the cardiovascular system functioning and respiration in cats]. | 2005 Jul-Aug |
|
| [Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential of their practical application]. | 2006 Mar-Apr |
|
| [Selank-induced normalizing effects on the integrative brain activity and biogenic amine level disorders due to antenatal hypoxia]. | 2006 Nov |
|
| [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. | 2008 |
|
| Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. | 2008 Jul-Aug |
|
| [Effects of heptapeptide selank on genetically-based and situation-provoked symptoms of depression in behavior in WAG/Rij and Wistar rats, and in BALB/c mice]. | 2008 Mar-Apr |
|
| [Compensatory and antiamnestic effects of heptapeptide Selank in monkeys]. | 2008 May-Jun |
|
| [Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/C and C57Bl/6 mice: a comparative study]. | 2008 Sep-Oct |
|
| [Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with PCPA]. | 2009 Jul-Aug |
|
| Transcriptomic response of rat hippocampus and spleen cells to single and chronic administration of the peptide selank. | 2010 Jan-Feb |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SELANK
Created by
admin on Sat Dec 16 15:39:59 GMT 2023 , Edited by admin on Sat Dec 16 15:39:59 GMT 2023
|
PRIMARY | Selank is a synthetic analogue of the immunomodulatory peptide tuftsinas such, it mimics many of its effects. It has been shown to modulate the expression of Interleukin-6 (IL-6) and affect the balance of T helper cell cytokines. It has been shown to influence the concentration of monoamine neurotransmitters and induce metabolism of serotonin. Selank has also been found to rapidly elevate the expression of brain-derived neurotropic factor (BDNF) in the hippocampus of rats. | ||
|
TS9JR8EP1G
Created by
admin on Sat Dec 16 15:39:59 GMT 2023 , Edited by admin on Sat Dec 16 15:39:59 GMT 2023
|
PRIMARY | |||
|
129954-34-3
Created by
admin on Sat Dec 16 15:39:59 GMT 2023 , Edited by admin on Sat Dec 16 15:39:59 GMT 2023
|
PRIMARY | |||
|
SELANK
Created by
admin on Sat Dec 16 15:39:59 GMT 2023 , Edited by admin on Sat Dec 16 15:39:59 GMT 2023
|
PRIMARY | |||
|
TS9JR8EP1G
Created by
admin on Sat Dec 16 15:39:59 GMT 2023 , Edited by admin on Sat Dec 16 15:39:59 GMT 2023
|
PRIMARY | |||
|
2049928
Created by
admin on Sat Dec 16 15:39:59 GMT 2023 , Edited by admin on Sat Dec 16 15:39:59 GMT 2023
|
PRIMARY | |||
|
11765600
Created by
admin on Sat Dec 16 15:39:59 GMT 2023 , Edited by admin on Sat Dec 16 15:39:59 GMT 2023
|
PRIMARY | |||
|
DTXSID701029276
Created by
admin on Sat Dec 16 15:39:59 GMT 2023 , Edited by admin on Sat Dec 16 15:39:59 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
